Lv4
684 积分 2024-01-17 加入
GPC3-specific dnTGFβRII-armoured CAR T cells for hepatocellular carcinoma
8天前
已完结
Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial
12天前
已完结
Impact of Treatment Sequencing with CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model
12天前
已完结
Higher Relapse Rate in HBeAg-Negative Patients After Cessation of Tenofovir Alafenamide Compared With Entecavir or Tenofovir Disoproxil Fumarate
19天前
已完结
Switching to Entecavir >3 Months Before the End of Tenofovir-Based Therapy in Hepatitis B e Antigen-Negative Patients May Reduce Early Relapse and Hepatitis Flare
19天前
已完结
Does ciltacabtagene autoleucel have a future in multiple myeloma?
1个月前
已完结
Antibody–Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond
1个月前
已关闭
HBV Reactivation in Patients with Hepatocellular Carcinoma Treated with PD-1/-L1 Antibodies and Concurrent Antiviral Prophylaxis Agents: A Prospective Observational Study
1个月前
已完结
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy
1个月前
已关闭
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy
1个月前
已完结
皖公网安备34019202002308
